CatalystWireBeta

UK small-cap RNS · 3 Aug 2026

Every announcement of UK small & mid caps under £2bn. The ones that started or moved a situation are marked – a click opens it.

Sort: Newest · Largest companies
  1. 17:56
    Holding(s) in Company Holding
  2. 16:10
    Holding(s) in Company Holding
  3. 14:00
    Director/PDMR Shareholding Director dealing
  4. 09:26
    Holding(s) in Company Holding
  5. 09:17
    Holding(s) in Company Holding
  6. 07:01
    Corporate and Strategic Update
    New management starts a portfolio-wide review to run Alien as a project generator and seek to crystallise value, with iron ore monetisation prioritised for funding; no outcomes yet and a later equity raise is not ruled out.
    Sale process / strategic review outlook mixedfirst in 1 year +6.7% on the day
    Moved: new: Portfolio review and monetisation – Portfolio-wide review begun under new management · Board and management reshuffle: Changes effective; handover under way → New team sets strategy
  7. 07:00
    Launch of Power & Energy Services Division
    Creates a separately reported Power & Energy Services division under Marcus White, following Advantage NRG's £20.8m of FY2026 contracted works, to scale the one area of momentum after a weak H1.
    Transformational contract / build-out £20.8m · 69% of mcapoutlook positivefirst since Oct 2023 +6.0% on the day
    Moved: Power and energy sector expansion: Advantage NRG integrated; 70% of Lyons acquired → Dedicated division launched 3 Aug 2026
  8. 07:00
    Filing of criminal complaint
    Celsius has filed a criminal complaint against its former chair, who now advises Kiri, Sodor and PMR. This escalates the MMCI/MCB dispute and adds legal cost and uncertainty. Directors also face Sodor's Anti-Dummy Law complaints.
    Legal & regulatory +10.0% on the day
    Moved: Sodor 60% MCB interest transfer: Arbitration ongoing; Celsius's 40% MMCI stake now threatened → Arbitration ongoing; criminal complaints on both sides · MCB copper-gold project development: Foreclosure and auction notices issued on 17 July → Foreclosure notices issued; dispute escalating
  9. 07:00
    Provisional plan re proposed move to Aquis
    Gives a provisional timetable for the Main Market cancellation and Aquis admission on 1 September 2026, a long-awaited step for the gold pivot. Dates may change and funds and board are not yet named.
    Delisting / take-private outlook mixed −11.8% on the day
    Moved: Main Market delisting to Aquis: Admission still pending; governance changes tied to it → Provisional timetable set; admission targeted 1 September · Fundraise before end March: Still deferred; further raises expected → Still unraised; tied to Aquis admission
  10. 07:00
    Commissioning Commenced at Hillside Gold Project
    Commissioning commenced at Kavango's Hillside Gold Project following successful processing plant installation
    Project milestones outlook positive +7.4% on the day
    Moved: Hillside gold development and plants: Funded for expansion; commissioning pending → Plant installed; commissioning under way since 1 July
  11. 07:00
    Quarterly NAV Announcement and Trading Update Trading update
    NAV per share slipped 2.1% to 131.09p, the third straight quarterly fall, as Starling's carrying value dropped 5% on peer valuations. Deep Instinct was fully written down and wefox took an uncertainty discount.
    Disposal of a part (break-up) outlook mixed +0.7% on the day
    Moved: Maintain a cash buffer of up to £50m: pending → changed – The cash buffer has run down to £1.0m gross cash, and Klarna shares are being sold to fund working capital. · Klarna IPO lock-up: Partial sale done; residual holding $75.6m → Further Klarna sales funding working capital · Shareholder consultation and structural review: Orderly realisation under way; self-managed handover → Debt repaid; handover to self-management imminent
  12. 07:00
    New UK clinical guideline for MT-RNR1 testing
    - Guideline recommends MT-RNR1 testing before aminoglycoside treatment and supports point-of-care testing in acute care settings
    Project milestones +0.0% on the day
    Moved: NHS England MT-RNR1 national tender: Pre-market engagement; NICE guidance due ~July 2027 → Pre-market engagement; new UK guideline supports adoption
  13. 07:00
    Directorate Change Board change
    Co-founder and Executive Chair of 26 years leaves the Board on medical advice, mid strategic review and offer period. Interim Chair is in place and the CEO is unchanged, which limits disruption.
    Sale process / strategic review first in 10 months +0.0% on the day
    Moved: Strategic review and possible offer: Review ongoing; talks with selected third parties → Review ongoing; Chair departs; no outcome stated
  14. 07:00
    Director/PDMR Shareholding Director dealing
  15. 07:00
    Audited Full Year Results Results
    Audited results confirm the cost reset: profit before tax of £0.2m against a £2.3m loss and cash of £2.1m. Revenue is flat on a like-for-like basis, and ARR and MRR fell after the lost retailer contract.
    Turnaround plan with targets outlook mixedfirst in 8 months +0.0% on the day
    Moved: Turnaround and churn reduction: New win adds to rebuild; FY27 base still lower → Audited FY26 results show profit; rebuild under way
  16. 07:00
    RWS agrees to acquire Acogroup
    Binding deal to buy Acolad (FY25 revenue £182m, adjusted EBITDA £13m) at an EV of 2x adjusted EBITDA, funded from existing facilities. Adds European enterprise clients and regulated-industry exposure; completion needs French works council consultation and regulatory clearance.
    Large acquisition / reverse takeover £22.4m · 4% of mcap3 acquisitions in 3 months – usually less than 1 +14.8% on the day
    Moved: new: Acquisition of Acogroup (Acolad) – Binding put option signed; works council consultation
  17. 07:00
    Unaudited HY Results - Six Months Ended 30.06.26 Results
    Record H1 revenue of £21.8m came with gross margin down to 17.0%, a £4.8m Mace cash collection delay, cash of £0.4m and net debt up to £2.2m, after a run of guidance cuts.
    Dilutive fundraise £21.8m · 1982% of mcapoutlook mixedfirst since Oct 2023 −9.5% on the day
    Moved: FY2025 revenue slippage into 2026: FY26 guidance cut after pipeline review → H1 results; trading in line with cut guidance · CEO succession: Interim CEO restructuring costs → Restructuring largely done; Board cut to three · Working capital funding for solar programme: Repayment expected ahead of due date → Loan part repaid; remainder extended
  18. 07:00
    H1 FY26 Trading Update Trading update
    The Board only confirms FY26 EBITDA in line with consensus (£10m-£11.1m). It is not a raise, but it follows May's guidance of the lower end of expectations and revenue slightly below.
    Turnaround plan with targets £20.0m · 27% of mcapin lineoutlook mixedfirst since Oct 2023 +0.0% on the day
    Moved: OEM customer order weakness: Early signs of stabilisation; FY26 still lower → OEM ARR down to £13.7m; still weak · Delayed UK customer projects: Projects progressing; revenue due in FY26 → Still delayed by component shortages · Accelerated FY26 investment programme: Announced; FY26 spend weighs on EBITDA → Progressing to plan; margin 13.2%
  19. 07:00
    Second Phase Contract Win & New Project Update
    A second-phase €1.7m contract from a repeat European satellite customer turns an earlier feasibility study into funded development. It adds Space and Communications NRE revenue, though it is small and development-stage.
    Segment turn £1.5m · 1% of mcap4 new orders in 3 months – usually about 2 +4.8% on the day
    Moved: Space communications ASIC pipeline: Follow-on ENS92040 ASSP orders received → Second-phase payload ASIC contract won; 5G user terminal project joined
  20. 07:00
    Second Quarter Results Results
    Net income of $185m, free cash flow of ~$89m and net debt of ~$2.56bn support the debt-reduction story, though production of ~71,400 boepd is below Q1's record and GTA slipped to ~2.65 mtpa.
    Project milestones outlook positive −5.9% on the day
    Moved: 2026 and 2027 debt maturities: Net debt down; RBL refinancing talks due → RBL refinancing under way, targeted Q4 · Tiberius development: FID taken; farm-down progressing → Farm-down completed July 2026; development under way · Jubilee drilling campaign: J76 online; J77 and J50 next → J76 and J77 online; J50 imminent
  21. 07:00
    Q2 2026 Overview &Unaudited Group Financial Update
    Selva Malvezzi gas sales rose to £1,203k from £912k on higher gas prices, and Tarba's funding need is falling. Group cash dipped only slightly to £852k after Poland licence fees and Selva royalty and tax payments.
    New CEO / reset £1.2m · 5% of mcapoutlook positive −1.7% on the day
    Moved: El Romeral transformer and power outage: Rental transformer installed; production restarted → Generating 15 hours/day; new transformer due September · Selva Malvezzi development wells and 3D: 3D seismic processing under way → EIA lodged with MASE; 3D processing continuing · Poland licence applications: San and Dunajec licences awarded → Licences accepted; Mniszów resource work done
  22. 07:00
    Rapid pneumonia test deployed for NHS patients
    The Ventilator-Acquired Pneumonia test, or 'VAP' test, enables rapid and informed changes to antibiotic prescribing and enhancement of clinical care in critically ill patients.
    Project milestones outlook positive −2.4% on the day
    Moved: Pneumonia test NHS launch: development complete, launch planned → Deployed in Addenbrooke's ICU; regulatory approval pending
  23. 07:00
    Final Results Results
    Accounts filed on time, with a first reported profit since listing, but the profit comes from disposing of the legacy US assets. The audit again carries disclaimers of opinion.
    Balance-sheet stress / refinancing outlook mixedfirst in 8 months +0.0% on the day
    Moved: Reorganisation under RMD Group: Counsel advice received; valuation underway → Counsel opinion received; shell status confirmed by FCA · Suspension, going concern and pledged shares: CLN3 being finalised; SPARK engaging FCA → FY26 accounts filed, disclaimers of opinion remain
  24. 07:00
    Half-year Results Results
    Board says first-half performance matched its expectations, so no guidance raise; profit still fell 38% at adjusted operating level and the interim dividend was halved, though assigned consultants rose for the first time since 2023.
    Segment turn in lineoutlook mixedfirst since Oct 2023 −6.7% on the day
    Moved: Consultant demand and utilisation recovery: Modest uptick continues, Middle East uncertainty added → First half-year rise in assigned consultants since 2023
  25. 07:00
    Clarkson CKN £1,525m
    Half-year Results Results
    After a first-half record and a prior 'enhanced confidence' stance, the Board now expects the full year well above consensus, a clear step up from the May wording and the 2025 profit fall.
    Upgrade / downgrade cycle ahead of expectationsoutlook positive, raisedfirst since Oct 2023 +9.0% on the day
    Moved: Zuma Labs integration and expansion: Trading in line with acquisition expectations → Completed; integrating, in line with expectations · Link Group acquisition and integration: Integration; trading in line with acquisition expectations → Completed; integrating, in line with expectations

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note